About the Authors

The Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord

jyoung@uhbs.ch

Membership of COHERE is provided in the Acknowledgments.

Competing Interests

HCB has received travel grants, honoraria and unrestricted research grants from various pharmaceutical companies, including GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMS), Gilead, Janssen, Roche, Abbott, Tibotec, Boehringer-Ingelheim, and ViiV Healthcare; HF has received payment for participation on advisory boards, unrestricted educational grants or travel grants from Abbott, BMS, ViiV Healthcare, Roche, Gilead, MSD, Boehringer-Ingelheim, and Tibotec-Janssen, and unrestricted research support from Gilead, MSD, and Roche; FG has received honoraria for participation on advisory boards, unrestricted educational grants or travel grants from Abbott, BMS, ViiV Healthcare, Gilead, MSD, Boehringer-Ingelheim, and Tibotec-Janssen; GC has received honoraria from Roche; PR has served as a scientific advisor to Boehringer Ingelheim Pharmaceuticals, BMS, Gilead Sciences, GSK, ViiV Healthcare, Merck, Theratechnologies, Tibotec Therapeutics, Tobira Therapeutics, and Ferrer, has served on data and safety monitoring boards and endpoint adjudication committees for Tibotec Therapeutics, has received honoraria for speaking engagements at scientific conferences from Boehringer Ingelheim Pharmaceuticals, BMS, Gilead Sciences, GSK, and Theratechnologies, has received research support from Gilead Sciences, ViiV Healthcare, Tibotec, BMS, Merck, Abbott, and Boehringer Ingelheim Pharmaceuticals; JMM has received payment for participation on advisory boards, consultancy or lecturing from Abbott, Boehringer-Ingelheim, BMS, Cubist, GSK, Gilead Sciences, Janssen-Cilag, Merck, Novartis, Pfizer, Roche, Schering-Plough, Theravance, and ViiV. JY, MP, LM, SA, SG, FR, BG, MS, NO, OK, AC, SDW, JM, JK, CC, and JG all declare no conflicts of interest.

Author Contributions

Conceived and designed the experiments: HB JY. Contributed the data: MP LM SA SG FR PR BG MS FG NO OK JMM HF AC SW JM HB. Analyzed the data: JY. Wrote the first draft of the manuscript: JY. Contributed to the writing of the manuscript: JY NO SG LM SW OK FG PR HF JMM GC HB. ICMJE criteria for authorship read and met: JY MP LM SA SG FR PR BG FG NO OK JMM HF AC SW JM JK CC JG GC HB. Agree with manuscript results and conclusions: JY MP LM SA SG FR PR BG MS FG NO OK JMM HF AC SW JM JK CC JG GC HB. Data management: JK CC. Project management: JG GC.